Table 6 Pharmacokinetic parameters of NAR and NAR-HNPs in normal rats.

From: Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway

Treatment

Parameters

t ½ (h)

λz (h−1)

C max (µg/ml)

T max (h)

AUC 0-∞ (µg ml h−1)

MRT (h)

AUMC 0-∞ (µg ml h−1)

Vz/F (mg/kg) (µg/ml)

CL/F (mg/kg) (µg/ml)

NAR (50 mg/kg)

4.496 ± 0.207

0.154 ± 0.007

0.504 ± 0.026

4 ± 0.0

4.569 ± 0.217

8.326 ± 0.272

38.15 ± 0.287

71.12 ± 3.202

10.97 ± 0.555

NAR-HNPs (50 mg/kg)

10.26* ± 1.21

0.695* ± 0.009

0.670 ± 0.067

4 ± 0.0

6.897* ± 0.281

15.56* ± 1.784

108.3* ± 15.91

106.6* ± 9.15

7.268* ± 0.3028

  1. Results are stated as mean ± S.E.M. (n = 6)* vs corresponding NAR group. NAR, naringenin; NAR-HNPs, naringenin-loaded hybridized nanoparticles; t ½, elimination half-life; λz, elimination rate constant; C max, maximum plasma concentration; tmax, time to reach C max; AUC 0-∞, area under the plasma concentrations-time curve; MRT, mean residence time; AUMC0-∞, area under the first moment curve; Vz/F, volume of distribution; CL/F, clearance.